DiaMedica Therapeutics Inc.
corporate_fare Company Profile
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for DMAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for DMAC spans 8-K, 10-Q, DEF 14A.
Recent high-impact activity:
- DiaMedica Q3 Loss Widens to $11.3M; ReMEDy2 Hits 200-Patient Interim Analysis Threshold
- DiaMedica Q2 Loss Widens to $10.1M; ReMEDy2 Stroke Trial Hits 85% Enrollment, Interim Analysis Set for Q1 2027
- DiaMedica's Preeclampsia Drug Shows Strong Blood Pressure Reductions in Phase 2
- Shareholders Approve 3.5M Share Increase for Incentive Plan
- DiaMedica's Pivotal Stroke Trial Reaches 75% Enrollment, Signaling Progress After Prior Delays
Financial Snapshot
Short Interest & Short Volume
24.77 days to coverFINRA reported short interest of 5,018,365 shares in DMAC as of the October 30, 2026 settlement, a 4.2% decrease from the prior period — about 24.8 days to cover at its recent average daily volume. On November 20, 2026, 32.9% of DMAC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.